<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01038648</url>
  </required_header>
  <id_info>
    <org_study_id>SITAGLIPTIN-003 IDRF</org_study_id>
    <nct_id>NCT01038648</nct_id>
  </id_info>
  <brief_title>Sitagliptin in Prevention of Type 2 Diabetes Mellitus</brief_title>
  <acronym>SITAGLIPTIN</acronym>
  <official_title>Does the DPP4 Inhibitor Sitagliptin Have a Role in Preventing Type 2 Diabetes- A Randomised Controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>India Diabetes Research Foundation &amp; Dr. A. Ramachandran's Diabetes Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>India Diabetes Research Foundation &amp; Dr. A. Ramachandran's Diabetes Hospitals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis is, in subjects with persistent impaired glucose tolerance(IGT) , sitagliptin
      will decrease the conversion rate to diabetes as compared to a placebo in three years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The DPP-4 inhibitor Sitagliptin may be a suitable preventive agent in subjects with IGT or
      IFG on account of observed functional improvements in islet cell function and potential
      protective effect on beta cell mass.

      Objectives of the study

        1. Primary objectives :

           - To test whether the DPP4 inhibitor Sitagliptin is effective in preventing conversion
           of IGT to diabetes when compared with a placebo.

        2. Secondary objectives:

             -  To assess rates of reversal from IGT to Normal Glucose Tolerance (NGT) in IGT
                patients administered Sitagliptin

             -  To assess the effect of Sitagliptin on measure of beta cell function and insulin
                resistance in patients with IGT.

      Study design

      Double blind placebo controlled, parallel group study - three years follow up .

      Subjects with IGT in the age group of 30-55 years (n=900) will be identified by screening
      with a standard OGTT. Selected subjects will be randomized to the control arm using placebo
      and the two study arms using Sitagliptin. At baseline all group will receive a standard
      advice on lifestyle modification. The dose of sitagliptin will be 100 mg/d. The subjects will
      be reviewed at 6 monthly intervals and repeat OGTT will be done annually.

      Proforma containing details of anthropometry, occupation, physical activity, diet habits,
      details of medications, regularity of treatment and biochemical investigations will be filled
      up at each interview.

      Investigations:

      Initial Screening

        1. Demographic data

        2. Height, weight, waist and hip measurements.

        3. Details of family history of diabetes, hypertension and cardiovascular diseases.

        4. History of any other major illness.

        5. History of blood pressure and measurements.

        6. Details of education and occupation.

        7. Diet habits will be analyzed by dietician.

        8. Details of physical activity will be assessed by a questionnaire.

      Laboratory investigations:

        1. Initial OGTT

        2. Plasma glucose and HbA1c.

        3. Lipid profile

        4. Liver function tests

        5. Serum amylase and serum lipase

        6. Plasma insulin

        7. 12 lead ECG.

      Review analysis:

        1. Review will be done with all clinical and biochemical assessment annually.

        2. Evaluation of adherence to prescription will be done at 6 monthly intervals.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1. Rate of conversion of IGT to diabetes. 2. Relative reduction of incidence of diabetes by Sitagliptin among people with IGT compared to Placebo. 3. Increase in reversal of IGT to NGT</measure>
    <time_frame>At intervals -6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Beneficial effects in beta cell function. 2. Changes in insulin resistance 3. Improvement in cardiovascular risk factors by Sitagliptin.</measure>
    <time_frame>Annual</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Advice life style at baseline only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sitagliptin arm : 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100mg/day sitagliptin
advice on life style modification at baseline only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>100mg/day</description>
    <arm_group_label>sitagliptin arm : 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>life style modification at base line</intervention_name>
    <description>Advice on physical activity, diet and drug adherence.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects with IGT in the age group of 30-55 years (n=900) will be identified by screening
        with a standard OGTT.

        Exclusion Criteria:

          1. Known diabetes

          2. Pregnant women

          3. Alcohol abuse

          4. Transferable jobs.

          5. Subjects with major illness like cancer, hepatic or cardiac diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dr.Ambady Ramachandran</name>
      <address>
        <city>Chennai</city>
        <state>Tamil nadu</state>
        <zip>600 008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>1.Ramachandran A, Ronald Ma, Snehalatha C. Diabetes in Asia. 2009 Lancet Oct;DOI:10.1016/S0140-6736(09)60937-5. 2.Snehalatha C, Mary S, Selvam S, Sathish Kumar CK, Shetty SB, Nanditha A, Ramachandran A. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme-1 (IDPP-1).Diabetes Care. 2009 Oct;32(10):1796-801. 3.Ramachandran A, Snehalatha C, Mary S, Selvam S, Sathish Kumar CK, Catherin Seeli A, Samith Shetty A. Pioglitazone does not enhance effectiveness of life style modification in prevening conversion of impaired glucose tolerance to diabetes in Asian Indians-Results of Indian Diabetes Prevention Programme- (IDPP-2).Diabetologia 2009; 52: 1019 - 1026. 4.Ramachandran A, Snehalatha C. Cardiovascular risk factors in normoglycaemic Asian Indian population-Impact of urbanization. Diabetologia 2009 52; 596-599.</citation>
  </reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2009</study_first_submitted>
  <study_first_submitted_qc>December 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2009</study_first_posted>
  <last_update_submitted>December 29, 2015</last_update_submitted>
  <last_update_submitted_qc>December 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2015</last_update_posted>
  <responsible_party>
    <name_title>A. Ramachandran / Chairman / Managing Director / President</name_title>
    <organization>IDRF &amp; ARH</organization>
  </responsible_party>
  <keyword>Sitagliptin</keyword>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Prevention of type 2 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

